Statens Serum Institut is succesful in arbitration proceedings

Statens Serum Institut is successful to obtain rights for the production and sale of antibodies.

On 3 December 2018 Statens Serum Institut terminated its agreement with BioPorto Diagnostics A/S regarding certain rights to produce and sell antibodies, and products (kits) based on antibodies that originates from Statens Serum Institut.

In a ruling of 25 October 2019 issued by an arbitration tribunal formed under The Danish Institute of Arbitration, the termination of the agreement with BioPorto Diagnostics A/S was deemed to be lawful and in accordance with the parties' agreement. BioPorto Diagnostics A/S hence holds no rights to sell or produce antibodies, or products (kits) based on antibodies that originates from Statens Serum Institut.

The arbitration ruling does not affect antibodies or products (kits) purchased by customers of BioPorto Diagnostics A/S in the period between December 3, 2018 and October 25, 2019.

Further information

For information about antibodies, see: antibodies.ssi.dk

For further questions, please contact: CFO Helle Birk Krogsgaard on phone +45 32 68 31 14

Helle Birk Krogsgaard

Contact

Helle Birk Krogsgaard, Executive Vice President, CFO, Forretn.supp og Campus - Ledelse og stab / Forretningssupport og Campus
T. +45 32683114 @. hbi@ssi.dk View profile